JPMorgan Upgrades Apellis Pharma to Overweight on Pipeline Momentum and Regulatory Outlook

JPMorgan Chase has assigned an 'Overweight' rating to Apellis Pharma (APLS), citing improved near-term catalysts from ongoing clinical trials and anticipated regulatory decisions. The firm highlighted Phase 3 trial results for pegcetacoplan in geographic atrophy, a late-stage form of age-related macular degeneration, as a key driver for the upgrade. Data from the Phase 3 GATHER trial showed a statistically significant reduction in lesion growth, with a 21% slowing rate compared to placebo at 12 months (p<0.001). The analyst team underscored that if the FDA approves the drug for geographic atrophy by mid-2026, Apellis could capture a meaningful share of the estimated $2.3 billion U.S. market for this condition. The company has already submitted a Biologics License Application (BLA) in December 2025, with a PDUFA decision date set for June 2026. JPMorgan’s base-case valuation model now projects $2.8 billion in peak annual sales for pegcetacoplan in this indication alone. Market reaction has been positive, with APLS shares rising 14% in pre-market trading following the announcement. The upgrade also reflects confidence in Apellis’s broader pipeline, including Phase 2 trials in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, where early data suggest favorable safety and efficacy profiles. The firm expects multiple data readouts between Q3 2026 and Q1 2027, which could further de-risk the portfolio. Investors and institutions tracking biotech sentiment may view the JPMorgan move as a signal of improving risk-reward balance for APLS, especially given the company’s current market capitalization of approximately $18 billion and a cash runway extending into 2028.